American Portfolios Advisors’s Harvard Bioscience HBIO Stock Holding History

American Portfolios Advisors’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-20	Closed	-$720	–	3563
2022 Q2	$720	Hold	20	–	–	﹤0.01%	3340
2022 Q1	$1.24K	Hold	20	–	–	﹤0.01%	3322
2021 Q4	$1.41K	Hold	20	–	–	﹤0.01%	3257
2021 Q3	$1.4K	Buy	+20	New	+$1.59K	﹤0.01%	3238

Other funds holding HBIO

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

ACM

Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

American Portfolios Advisors's HBIO Position: Q3 2022 in Review

American Portfolios Advisors sold out of Harvard Bioscience (HBIO) in Q3 2022, closing a stake of 20 shares — an estimated $720 sold.

American Portfolios Advisors first reported a position in HBIO in Q3 2021 and held it in 4 quarters. The position peaked at $1.41K in Q4 2021. 79 funds tracked by Wall St. Rank hold HBIO as of Q3 2022.

American Portfolios Advisors reported no remaining Harvard Bioscience position as of Q3 2022 after selling out during the quarter.
American Portfolios Advisors sold 20 Harvard Bioscience shares in Q3 2022, an estimated $720.
American Portfolios Advisors first reported a position in Harvard Bioscience in Q3 2021 and held it in 4 quarters.
American Portfolios Advisors's Harvard Bioscience position peaked at $1.41K in Q4 2021.
79 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.